Semaglutide has a Highlights Semaglutide (Wegovy) is an FDA-approved medication for diabetes and weight loss
This blog provides an in-depth look at the ongoing litigation involving Semaglutide, offering crucial guidance for potential claimants and insights into how these legal battles may influence pharmaceutical practices and patient safety
Obesity has impacts on cardiovascular disease outcomes through increased risk of coronary artery disease, heart failure (more prominent with preserved ejection fraction), cardiac arrhythmias (most significantly atrial fibrillation), sudden death, and venous thromboembolism [7]
It included detailed claims about the product, which it said was perfect for people with big appetites or anyone whos tried GLP-1 drops or injections without much result
A new briefing from the Californian-based think tank Pacific Research Institute (PRI) warns that continued large-scale sales are not only putting patients at risk but could wipe out between $9.3bn and $11.8bn in future R&D investment enough to cost the world four to five new medicines
